Table 1 Participant characteristics.

PET imagingCSF
Mean (SD)/n (%)
(N = 38)
Mean (SD)/n (%)
(N = 104)
Age (years)73.8 (5.3)74.57 (5.20)
Sex
  Men
  Women
18 (47.4)
20 (52.6)
59 (56.7)
45 (43.3)
Race
  African-American
  Caucasian
  Asian
  More than one
3 (7.9)
35 (92.1)
0 (0.0)
0 (0.0)
11 (10.6)
92 (88.5)
0 (0.0)
1 (1.0)
CDR
  0
  0.5
29 (76.3)
9 (23.7)
83 (79.8)
21 (20.2)
ApoE4
  Negative
  Positive
25 (65.8)
13 (34.2)
58 (55.8)
45 (43.3)
Sleep medications
  Yes
  No
4 (10.5)
34 (89.5)
12 (11.5)
92 (88.5)
AHI (respiratory events/hour)*
  Negative (AHI < 5)20 (52.6)38 (36.5)
  Mild (AHI 5–15)13 (34.2)43 (41.4)
  Moderate (AHI 15–30)5 (13.2)18 (17.3)
  Severe (AHI > 30)0 (0)5 (4.8)
PLMI (leg movements/hour)
  Negative (PLMI < 15)21 (55.3)49 (47.1)
  Low (PLMI 15–45)7 (18.4)33 (31.7)
  High (PLMI > 45)10 (26.3)22 (21.2)
AV-45 PET SUVR1.44 (0.61)
AV-1451 PET SUVR1.40 (0.49)
Aβ42 (pg/ml)1012.59 (367.94)
t-tau (pg/ml)245.46 (119.69)
p-tau (pg/ml)23.66 (13.46)
AD pathology
  Amyloid negative/tau negative20 (52.6)31 (29.8)
  Amyloid positive/tau negative9 (23.7)35 (33.7)
  Amyloid positive/tau positive8 (21.1)27 (25.9)
  Amyloid negative/tau positive1 (2.6)11 (10.6)
Time interval from scan/lumbar puncture to sleep study (years)
  AV-45 PET0.29 (0.48)1.00 (2.60)
  AV-1451 PET0.29 (0.40)

*For the participants who underwent PET imaging (N = 38), 4 of 38 participants used continuous positive airway pressure therapy during sleep monitoring. For participants with CSF (N = 104), 12 of 104 participants used continuous positive airway pressure therapy and 1 participant used lateral position therapy device during sleep monitoring.